LEGN vs. TEVA, BGNE, GMAB, VTRS, ITCI, SMMT, MRNA, RDY, CTLT, and SRPT
Should you be buying Legend Biotech stock or one of its competitors? The main competitors of Legend Biotech include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry.
Legend Biotech vs.
Teva Pharmaceutical Industries (NYSE:TEVA) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, community ranking, institutional ownership, analyst recommendations and media sentiment.
Legend Biotech has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Legend Biotech is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
Teva Pharmaceutical Industries received 1243 more outperform votes than Legend Biotech when rated by MarketBeat users. However, 72.03% of users gave Legend Biotech an outperform vote while only 67.82% of users gave Teva Pharmaceutical Industries an outperform vote.
Teva Pharmaceutical Industries has a net margin of -5.73% compared to Legend Biotech's net margin of -66.92%. Teva Pharmaceutical Industries' return on equity of 42.92% beat Legend Biotech's return on equity.
In the previous week, Teva Pharmaceutical Industries had 1 more articles in the media than Legend Biotech. MarketBeat recorded 11 mentions for Teva Pharmaceutical Industries and 10 mentions for Legend Biotech. Teva Pharmaceutical Industries' average media sentiment score of 1.07 beat Legend Biotech's score of 0.57 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.
Teva Pharmaceutical Industries presently has a consensus target price of $22.13, suggesting a potential upside of 1.21%. Legend Biotech has a consensus target price of $80.62, suggesting a potential upside of 132.52%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500.
54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Teva Pharmaceutical Industries beats Legend Biotech on 11 of the 18 factors compared between the two stocks.
Get Legend Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Legend Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:LEGN) was last updated on 1/21/2025 by MarketBeat.com Staff
